

## Senores Pharmaceuticals Limited IPO

**Senores Pharmaceuticals IPO Price:** ₹372 to ₹391 per share

**IPO Dates:** December 20, 2024 to December 24, 2024



### **About Senores Pharmaceuticals Limited**

Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a wide range of pharmaceutical products, primarily targeting regulated markets such as the US, Canada, and the UK. The company also extends its services to emerging markets worldwide.

#### **Product Portfolio:**

The company offers a variety of medicines, including Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Morphine Sulfate Tablets, and Ivermectin Tablets. These products cater to various therapeutic areas, including antibiotics, antifungals, and critical care.

#### **Key Milestones (as of September 30, 2024):**

- Launched **55 pharmaceutical products** in regulated markets.
- Operates in **43 countries** across emerging markets, offering critical care injectables and APIs.
- Maintains partnerships with distributors and hospitals across several states in India.

#### **Competitive Strengths**

1. **Presence in Regulated Markets:**  
Products tailored for the US, UK, and Canada, with a US FDA-approved manufacturing setup.
2. **Diverse Product Portfolio:**  
A comprehensive and differentiated range of pharmaceutical offerings developed within a short span.
3. **Strategic Partnerships:**  
Long-term marketing agreements with leading pharmaceutical companies in regulated markets.

4. **Emerging Market Focus:**  
Strong presence in emerging markets with specialized and complex product offerings.
5. **Innovative R&D:**  
Robust R&D capabilities driving product innovation and differentiation.
6. **Experienced Leadership:**  
A professional and skilled management team with extensive industry expertise.

## Senores Pharmaceuticals IPO Details

IPO Date	December 20, 2024 to December 24, 2024
Listing Date	[.]
Face Value	₹10 per share
Price Band	₹372 to ₹391 per share
Lot Size	38 Shares
Total Issue Size	1,48,87,723 shares (aggregating up to ₹582.11 Cr)
Fresh Issue	1,27,87,723 shares (aggregating up to ₹ 500.00 Cr)
Offer for Sale	21,00,000 shares of ₹10 (aggregating up to ₹82.11 Cr)
Issue Type	Book Built Issue IPO
Listing At	BSE, NSE
Share Holding Pre Issue	3,32,65,865 shares
Share Holding Post Issue	4,60,53,588 shares

## Senores Pharmaceuticals IPO Timeline (Tentative Schedule)

Senores Pharmaceuticals IPO IPO opens on December 20, 2024, and closes on December 24, 2024.

IPO Open Date	Friday, December 20, 2024
IPO Close Date	Tuesday, December 24, 2024
Basis of Allotment	Thursday, December 26, 2024
Initiation of Refunds	Friday, December 27, 2024
Credit of Shares to Demat	Friday, December 27, 2024
Listing Date	Monday, December 30, 2024
Cut-off time for UPI mandate confirmation	5 PM on December 24, 2024

## Senores Pharmaceuticals IPO Lot Size

Bidders have the opportunity to bid for a minimum of 35 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.

Application	Lots	Shares	Amount
Retail (Min)	1	38	₹14,858
Retail (Max)	13	494	₹1,93,154
S-HNI (Min)	14	532	₹2,08,012
S-HNI (Max)	67	2,546	₹9,95,486
B-HNI (Min)	68	2,584	₹10,10,344

## Senores Pharmaceuticals IPO Reservation

Investor Category	Shares Offered
QIB Shares Offered	Not less than 75% of the Net Issue
Retail Shares Offered	Not more than 10% of the Net Issue
NII (HNI) Shares Offered	Not more than 15% of the Net Issue

**APPLY NOW**

## Senores Pharmaceuticals Limited Financial Information (Restated Consolidated)

Senores Pharmaceuticals Limited's revenue increased by 457% and profit after tax (PAT) rose by 288% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended	30 Sep 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	678.08	621.88	131.05	59.15
Revenue	183.35	217.34	39.02	14.63
Profit After Tax	23.94	32.71	8.43	0.99
Net Worth	319.06	231.71	45.5	36.59
Reserves and Surplus	263.36	175.94	35.25	25.37
Total Borrowing	242.03	248.38	60.76	14.21

## Key Performance Indicator

The market capitalization of Senores Pharmaceuticals IPO is Rs 1350.70 Cr.

KPI as of Sun, Mar 31, 2024.

KPI	Values
ROE	23.60%
ROCE	11.73%
Debt/Equity	1.07
RoNW	23.60%
PAT Margin	15.25
Price to Book Value	5.84

## Objectives of the Senores Pharmaceuticals IPO

The company plans to utilize the net proceeds from the IPO for the following purposes:

- 1. Investment in Havix Group, Inc. (Aavis Pharmaceuticals):**
  - To fund capital expenditure for establishing a sterile injection manufacturing facility at the Atlanta Facility.
- 2. Repayment or Prepayment of Borrowings:**
  - To repay or prepay, either in full or partially, certain loans availed by the company.
- 3. Subsidiary Debt Repayment:**
  - Investment in Havix for the repayment or prepayment of borrowings availed by the subsidiary.
- 4. Working Capital Requirements:**
  - To fund the working capital needs of the company.
- 5. Support for Subsidiaries:**
  - Investment in subsidiaries, namely **Senores Pharmaceuticals Inc. (SPI)** and **Ratnatris Pharmaceutical Private Limited (Ratnatris)**, to support their working capital requirements.
- 6. Inorganic Growth and Strategic Initiatives:**
  - Funding acquisitions, other strategic initiatives, and general corporate purposes.

## Senores Pharmaceuticals IPO Prospectus

- > [Senores Pharmaceuticals IPO DRHP](#)
- > [Senores Pharmaceuticals IPO RHP](#)